Yahoo Canada Web Search

Search results

  1. Dec 19, 2016 · Sponsors hold a 13.18 percent stake in Beximco Pharmaceuticals, institutions 27.94 percent, foreign investors 37.84 percent and general investors the rest 21.04 percent, according to the DSE data ...

  2. Mar 25, 2021 · The Bangladeshi company was founded in 1976. Four years later, Beximco Pharmaceuticals started manufacturing products under the licences of Germany-based Bayer and Upjohn of the US, and launched its own formulation brands three years later. In 1985, it was listed on the Dhaka Stock Exchange. Today, Beximco manufactures and markets its own ...

  3. Beximco Pharmaceuticals Ltd. (Beximco Pharma) is an emerging generic drug player committed to providing access to affordable medicines. Company’s state-of-the-art manufacturing facilities have been accredited by the regulatory authorities of USA, Australia, European Union, Canada, and Brazil, among others, and it currently focuses on building presence in many emerging and developed markets ...

  4. BEXIMCO | Bangladesh Export Import Co. Ltd. Beximco Pharma commences export to the United States. --August 5, 2016. Beximco Pharmaceuticals Limited (“BPL”, “Beximco Pharma” or “Company”; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces it has ...

  5. Sep 21, 2020 · Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces it has received US Food and Drug Administration (FDA) approval for Flecainide Acetate (50, 100 and 150 mg tablets), an antiarrythmic drug used for ...

  6. Beximco Pharma was founded in 1976 and started operations in 1980, manufacturing products under the licenses of Bayer AG of Germany and Upjohn Inc. of United States. [5] Today, Beximco Pharma manufactures and markets its own branded generics for several diseases including AIDS , cancer , asthma , hypertension , and diabetes for both national and international markets.

  7. People also ask

  8. For further information please visit www.beximco-pharma.com or enquire to: Beximco Pharma Nazmul Hassan MP, Managing Director Tel: +880 2 58611001, ext.20080 S M Rabbur Reza Chief Operating Officer Tel: +880 2 58611001, ext. 20111 SPARK Advisory Partners Limited (Nominated Adviser) Mark Brady / Andrew Emmott Tel: +44 (0)20 3368 3551 / 3555

  1. People also search for